A Thiosemicarbazone Derivative as a Booster in Photodynamic Therapy-A Way to Improve the Therapeutic Effect

Int J Mol Sci. 2022 Dec 6;23(23):15370. doi: 10.3390/ijms232315370.

Abstract

Photodynamic therapy is one of the most patient friendly and promising anticancer therapies. The active ingredient is irradiated protoporphyrin IX, which is produced in the body that transfers energy to the oxygen-triggering phototoxic reaction. This effect could be enhanced by using iron chelators, which inhibit the final step of heme biosynthesis, thereby increasing the protoporphyrin IX concentration. In the presented work, we studied thiosemicarbazone derivative, which is a universal enhancer of the phototoxic effect. We examined several genes that are involved in the transport of the heme substrates and heme itself. The results indicate that despite an elevated level of ABCG2, which is responsible for the PpIX efflux, its concentration in a cell is sufficient to trigger a photodynamic reaction. This effect was not observed for 5-ALA alone. The analyzed cell lines differed in the scale of the effect and a correlation with the PpIX accumulation was observed. Additionally, an increased activation of the iron transporter MFNR1 was also detected, which indicated that the regulation of iron transport is essential in PDT.

Keywords: ABC transporters; heme; iron chelators; photodynamic therapy; phototoxic effect; thiosemicarbazone.

MeSH terms

  • Aminolevulinic Acid / pharmacology
  • Cell Line, Tumor
  • Heme / metabolism
  • Humans
  • Iron
  • Photochemotherapy* / methods
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Protoporphyrins / metabolism
  • Protoporphyrins / pharmacology
  • Thiosemicarbazones* / pharmacology

Substances

  • Thiosemicarbazones
  • Protoporphyrins
  • Aminolevulinic Acid
  • Photosensitizing Agents
  • Heme
  • Iron